Physician profile
Jill B Johnson
NPI 1508062134
$17,119.87
in general payments reported to CMS, 2019-2025
37 companies · $4,190 in 2025
The $4,190 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $281 · 2021: $1,223 · 2022: $2,663 · 2023: $3,515 · 2024: $4,297 · 2025: $4,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,747.72 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,417.25 | 2019-2025 | Evenity, Enbrel, Otezla |
| Janssen Biotech, INC. | $2,218.66 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,955.56 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,856.09 | 2019-2025 | |
| Pfizer INC. | $1,096.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,040.14 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $909.84 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $880.34 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $826.17 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.56 | 2020-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $422.19 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $319.47 | 2020-2025 | Acthar |
| Lilly USA, LLC | $302.40 | 2019-2025 | Taltz |
| Aurinia Pharma U.S., INC. | $291.81 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $288.74 | 2019-2025 | Tymlos |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $237.66 | 2019-2025 | Actemra |
| Organon LLC | $218.05 | 2023-2025 | Renflexis, Hadlima |
| Genzyme Corporation | $197.40 | 2019-2025 | |
| Depuy Synthes Sales INC. | $154.29 | 2020-2025 | Orthovisc, Monovisc |
| Alexion Pharmaceuticals, INC. | $112.78 | 2022-2024 | Strensiq |
| Horizon Therapeutics Plc | $97.89 | 2019-2023 | Krystexxa |
| Pacira Therapeutics, INC. | $86.68 | 2019 | |
| Zimmer Biomet Holdings, INC. | $81.19 | 2023-2024 | Gel-One Cross-Linked Hyaluronate |
| Mallinckrodt Enterprises LLC | $75.16 | 2019 | |
| Fidia Pharma USA INC. | $70.51 | 2022-2024 | Hymovis |
| Sobi, INC | $65.49 | 2019-2024 | |
| Fresenius Kabi USA, LLC | $64.98 | 2023-2024 | Idacio |
| Kiniksa Pharmaceuticals, LTD. | $63.21 | 2023 | Arcalyst |
| Invivyd INC | $57.92 | 2025 | Pemgarda |
| Medexus Pharma, INC. | $51.11 | 2019 | |
| Kyowa Kirin, INC. | $49.99 | 2023-2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $44.42 | 2021-2024 | Crysvita |
| Sandoz INC. | $42.52 | 2025 | Jubbonti, Hyrimoz |
| Pacira Pharmaceuticals Incorporated | $27.26 | 2023 | Zilretta, Iovera |
| Celgene Corporation | $24.98 | 2019 | |
| Mylan Institutional INC. | $21.50 | 2023 | Hulio |
| Orthogenrx INC. | $18.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.